Bayerscheringpharma.com (Text version)


Go to content
Service options
.
Contact us - Deutsche Version - Non-barrier-free application - Display options
Go to content
Current path
Bayer Schering Pharma / Therapeutic Areas / Therapeutic Areas A-Z / Infectious diseases
Go to content
Navigation
Go to Start page - Go to Sitemap

Content

Infectious diseases

We are surrounded by billions of bacteria. Many of them actually live on our skin or in our digestive tract. However, they have no business in the respiratory system, e.g. in the lungs. So when our natural barriers (for example the skin) are defective, even the most useful bacteria can become a mortal threat.

When our immune system is weakened – e.g. by smoking, viruses, other diseases, or old age – the result can be widespread infections such as bronchitis or pneumonia.

When the body's defenses fail

Although our immune system is able to protect us naturally from minor infections, these natural defenses become less effective when we are ill or grow old. In such cases, the result can be serious, even deadly infections. Then speed is of the essence, and an effective antibiotic is often required.

Before antibiotics were invented, there was little that a physician could do at such moments. It is not surprising, therefore, that the first antibiotics were seen as miracle cures in their time.

Indeed, scientists themselves believed they had conquered infectious diseases at the time. Yet the hope was deceptive. They had underestimated bacteria's ability to adapt and survive. The phenomenon of drug resistance appeared shortly after antibiotics came into common use. Today, some bacteria are resistant to a whole range of antibiotics. New substances are needed all the time if we are to remain one step ahead. Bayer Schering Pharma has produced some effective active ingredients in this context which today are important weapons in the fight against bacterial pathogens.

Especially common infections include respiratory- and urinary-tract infections.

Respiratory tract infections

A fundamental distinction is made between infections of the upper and lower respiratory tracts. Microbial inflammations of the tonsils (tonsilitis), the paranasal sinuses (sinusitis) and the middle ear (otitis) belong to the first group, infections of the bronchial tubes (bronchitis) and inflammations of the lungs (pneumonias) to the second.

Often, viruses are the first to affect organs and prepare the way for a subsequent bacterial infection. Typical bacterial pathogens are streptococcus and staphylococcus species and Haemophilus influenzae. Furthermore, other pathogens such as Moraxella catarrhalis can cause problems in the lower respiratory tract.

Sometimes, an untreated acute infection, e.g. of the paranasal sinuses or the bronchial tubes, can lead to serious complications. Early diagnosis and appropriate treatment – for example of acute sinusitis or acute bronchitis – are therefore important.

Urinary-tract infections

Infections of the urinary tract are among the most frequent of all infections. The urethra, the bladder, the kidneys or the prostate can be affected. Although (small) children can also have urinary-tract infections, susceptibility generally increases with age; women tend to be more frequently affected than men.

If an organism is otherwise healthy, such infections are usually straightforward. However, complications are possible in patients with diabetes or kidney problems and in pregnant women. Escheria-coli bacteria are the main trigger of infections of the bladder and urethra. Possible reasons for successful invasions by the bacteria can be inadequate personal hygiene, suppressed urination or sexual transmission. Symptoms include a strong and frequent urge to pass water, burning pain during urination, and cloudy urine containing blood. If they remain untreated, the pathogens can also reach the kidneys and trigger a painful inflammation of the kidneys, or nephritis.

Coli bacteria also play a role in bacterial infections of the prostate. Symptoms include colds, a temperature, and pain in the genitals and even in the back. Non-bacterial inflammations of the prostate gland are more frequent than bacterial ones.

top of page

Antibiotics with a history

Bayer Schering Pharma has over 70 years of experience of combating infectious diseases. Back in 1939, the Bayer researcher Gerhard Domagk was awarded the Nobel Prize for Medicine for the development of the antibiotic Prontosil. This product from the sulfonamide group of antibiotics had been chemically derived from dyes, then an important classes of products for Bayer.

In the 1980s and 90s, new active ingredients were developed from the class of fluorchinolones. One of these is still is use as an effective active ingredient against many bacterial pathogens – 25 years after its discovery. It is used primarily against infections of the urinary tract.

Another fluorochinolone has proved its worth against respiratory-tract infections in particular and has an especially rapid effect. Furthermore, it is also effective against other infections, e.g. of the skin or the abdomen.

top of page

Promoting responsible use

Bayer Schering Pharma is a strong proponent of using antibiotics responsibly. Because these drugs are a scarce resource, both physicians and patients must use them carefully in order to maintain their usefulness as long as possible for the benefit of all.

Advice for patients
Every body reacts differently to medicines. Therefore it is impossible to tell which medicine works best for you. Please consult your physician.

top of page
Image: child with clinical thermometer
Our Therapeutic Areas

Click here for more information about this topic.


General Conditions of Use - Privacy Statement - Imprint